Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;258(6):1126-32.
doi: 10.1007/s00415-010-5896-6. Epub 2011 Jan 8.

123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations

Francesc Valldeoriola  1 , Carles Gaig, Africa Muxí, Ignacio Navales, Pilar Paredes, Francisco Lomeña, Andres De la Cerda, Mariateresa Buongiorno, Mario Ezquerra, Pilar Santacruz, Maria Jose Martí, Eduardo Tolosa
Affiliations

123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations

Francesc Valldeoriola et al. J Neurol. 2011 Jun.

Abstract

Reduced uptake of (123)I- metaiodobenzylguanidine (MIBG) on cardiac gammagraphy and impaired odor identification are markers of neurodegenerative diseases with Lewy bodies (LB) as a pathological hallmark, such as idiopathic Parkinson's disease (IPD). LRRK2 patients present with a clinical syndrome indistinguishable from IPD, but LB have not been found in some cases. Patients with such mutations could behave differently than patients with IPD with respect to MIBG cardiac uptake and olfaction. We studied 14 LRRK2 patients, 14 IPD patients matched by age, gender, disease duration and severity, and 13 age and gender matched control subjects. Olfaction was analyzed through the University of Pennsylvania Smell Identification Test (UPSIT). MIBG cardiac uptake was evaluated through the H/M ratio. The late H/M was 1.44 ± 0.31 for LRRK2 patients, 1.19 ± 0.15 for PD patients, and 1.67 ± 0.16 for control subjects. LRRK2 patients presented lower but not statistically significant MIBG cardiac uptake than controls (p = 0.08) and significant higher uptake than PD patients (p = 0.04). UPSIT mean scores were 21.5 ± 7.3 for LRRK2 patients, 18.7 ± 6.2 for IPD patients and 29.7 ± 5.7 for control subjects. UPSIT score was lower in both LRRK2 and PD than in controls. In LRRK2 patients a positive correlation was found between myocardial MIBG uptake and UPSIT scores, (R = 0.801, p < 0.001). In LRRK2 patients, MIBG cardiac uptake was less impaired than in PD; a positive correlation between MIBG cardiac uptake and UPSIT scores was observed. As MIBG cardiac reduced uptake and impaired odor identification are markers of LB pathology, this findings may represent neuropathological heterogeneity among LRRK2 patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Scatter plot showing early (a) and late (b) H/M ratios for 123I-MIBG cardiac uptake in patients with idiopathic Parkinson’s disease (IPD), patients with parkinsonism and LRRK2 mutations (LRRK2-PD) and controls. Circles represent individual values; the bar refers to the mean H/M ratio in each group
Fig. 2
Fig. 2
Relationship between early (a) and delayed (b) H/M ratio for 123I-MIBG cardiac uptake and UPSIT scores in patients with parkinsonism and LRRK2 mutations. (Early: R = 0.62 p < 0.02; late: R = 0.68 p = 0.01)
Fig. 3
Fig. 3
UPSIT scores of patients with normal and abnormal delayed MIBG ratios
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.
    Saunders-Pullman R, Ortega RA, Wang C, Raymond D, Elango S, Leaver K, Urval N, Katsnelson V, Gerber R, Swan M, Shanker V, Alcalay RN, Mirelman A, Brumm MC, Mejia-Santana H, Coffey CS, Marek K, Ozelius LJ, Giladi N, Marder KS, Bressman SB. Saunders-Pullman R, et al. Neurology. 2022 Aug 23;99(8):e814-e823. doi: 10.1212/WNL.0000000000200737. Epub 2022 Jun 3. Neurology. 2022. PMID: 35995594 Free PMC article.
  • Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review.
    Pitton Rissardo J, Fornari Caprara AL. Pitton Rissardo J, et al. Brain Sci. 2023 Oct 18;13(10):1471. doi: 10.3390/brainsci13101471. Brain Sci. 2023. PMID: 37891838 Free PMC article. Review.
  • Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
    Pont-Sunyer C, Iranzo A, Gaig C, Fernández-Arcos A, Vilas D, Valldeoriola F, Compta Y, Fernández-Santiago R, Fernández M, Bayés A, Calopa M, Casquero P, de Fàbregues O, Jaumà S, Puente V, Salamero M, José Martí M, Santamaría J, Tolosa E. Pont-Sunyer C, et al. PLoS One. 2015 Jul 15;10(7):e0132368. doi: 10.1371/journal.pone.0132368. eCollection 2015. PLoS One. 2015. PMID: 26177462 Free PMC article.
  • Myocardial MIBG scintigraphy in genetic Parkinson's disease as a model for Lewy body disorders.
    Gabilondo I, Llorens V, Rodriguez T, Fernández M, Concha TP, Acera M, Tijero B, Murueta-Goyena A, Del Pino R, Cortés J, Gómez-Esteban JC. Gabilondo I, et al. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):376-384. doi: 10.1007/s00259-018-4183-0. Epub 2018 Oct 15. Eur J Nucl Med Mol Imaging. 2019. PMID: 30324423
  • International consensus statement on allergy and rhinology: Olfaction.
    Patel ZM, Holbrook EH, Turner JH, Adappa ND, Albers MW, Altundag A, Appenzeller S, Costanzo RM, Croy I, Davis GE, Dehgani-Mobaraki P, Doty RL, Duffy VB, Goldstein BJ, Gudis DA, Haehner A, Higgins TS, Hopkins C, Huart C, Hummel T, Jitaroon K, Kern RC, Khanwalkar AR, Kobayashi M, Kondo K, Lane AP, Lechner M, Leopold DA, Levy JM, Marmura MJ, Mclelland L, Miwa T, Moberg PJ, Mueller CA, Nigwekar SU, O'Brien EK, Paunescu TG, Pellegrino R, Philpott C, Pinto JM, Reiter ER, Roalf DR, Rowan NR, Schlosser RJ, Schwob J, Seiden AM, Smith TL, Soler ZM, Sowerby L, Tan BK, Thamboo A, Wrobel B, Yan CH. Patel ZM, et al. Int Forum Allergy Rhinol. 2022 Apr;12(4):327-680. doi: 10.1002/alr.22929. Int Forum Allergy Rhinol. 2022. PMID: 35373533 Free PMC article. Review.
See all "Cited by" articles

References

    1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607. doi: 10.1016/j.neuron.2004.11.005. - DOI - PubMed
    1. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet. 2005;365:415–416. - PubMed
    1. Gaig C, Ezquerra M, Martí MJ, Muñoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson’s disease: frequency, clinical features and incomplete penetrance. Arch Neurol. 2006;63:377–382. doi: 10.1001/archneur.63.3.377. - DOI - PubMed
    1. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol. 2005;57:918–921. doi: 10.1002/ana.20484. - DOI - PubMed
    1. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, et al. Biochemical and pathological characterization of LRRK2. Ann Neurol. 2006;59:315–322. doi: 10.1002/ana.20791. - DOI - PubMed

MeSH terms